Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant.

Pierre GallianAbdennour AmrounSyria LapercheSophie Le CamNadège BrisbarreLucile MalardElif NurtopChristine IsnardPascale RichardPascal MorelPierre TiberghienXavier de Lamballerie

Published in: Vox sanguinis (2022)

A fraction of CCP-V collected before November 2021 retains anti-Omicron seroneutralizing activity that may be selected by quantitative anti-IgG assays, but such assays do not easily allow the identification of 'high-titre' CCP-V. However, collecting plasma from vaccinated donors recently infected with Omicron may be the best option to provide optimal CCP-V for immunocompromised patients infected with this variant.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
high throughput
chronic kidney disease
respiratory syndrome coronavirus
prognostic factors
intensive care unit
mass spectrometry
extracorporeal membrane oxygenation